Bartner Lisa R, McGrath Stephanie, Rao Sangeeta, Hyatt Linda K, Wittenburg Luke A
Department of Clinical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA.
Can J Vet Res. 2018 Jul;82(3):178-183.
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
本研究的目的是确定大麻二酚（CBD）在健康犬体内的药代动力学。30只健康的实验犬被分配接受3种制剂中的1种（口服微囊化油珠、口服含CBD油或含CBD透皮乳膏），剂量为75mg或150mg，每12小时一次，共6周。在最初12小时内测定系列大麻二酚血浆浓度，并在第2、4和6周重复测定。口服含CBD油制剂观察到更高的全身暴露量，75mg和150mg剂量后的半衰期分别为199.7±55.9分钟和127.5±32.2分钟。暴露量与剂量成比例，口服含CBD油具有最有利的药代动力学特征。
